ArticlePloS one2026
Evaluation of HPV E6/E7 mRNA in predicting recurrence after Leep in cervical intraepithelial neoplasia: A study of negative findings.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical intraepithelial neoplasia (CIN) is a precursor to cervical cancer, and early detection of residual or recurrent disease is therefore critical for effective management. This study evaluated whether HPV E6/E7 mRNA status predicts recurrence in patients with CIN who underwent loop electrosurgical excision procedure (LEEP). People's Hospital of Nanning between January 2019 and July 2022 were included. Patients who underwent LEEP for high-grade cervical lesions at the First Follow-up commenced 4-6 months after LEEP and continued for 24 months; abnormal findings during this period prompted referral for colposcopy or cervical biopsy. Of the 91 patients, 3 (3.30%) experienced recurrence within 24 months. Recurrence rates were similar between patients with preoperative E6/E7 mRNA positivity (3.23%) and negativity (3.45%) (p = 0.956), and between postoperative E6/E7 mRNA status groups (5.26% in the negative group vs. 0% in the positive group; p = 0.814). Although 66.7% of patients shifted from positive to negative E6/E7 mRNA status after LEEP (p < 0.001), this change was not associated with recurrence risk. Preoperative E6/E7 mRNA yielded a sensitivity of 66.67% and specificity of 31.82%, whereas postoperative E6/E7 mRNA showed a sensitivity of 0% and specificity of 97.30%. In conclusion, E6/E7 mRNA status before and after LEEP did not predict recurrence in patients with CIN. Despite a significant reduction in E6/E7 mRNA positivity after surgery, its low sensitivity underscores the need for more effective biomarkers in follow-up care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.